title: Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.
abstract: AMG 102 is a fully human monoclonal antibody that selectively targets and neutralizes hepatocyte growth factor/scatter factor (HGF/SF). A detailed biochemical and functional characterization of AMG 102 was done to support its clinical development for the treatment of cancers dependent on signaling through the HGF/SF:c-Met pathway. In competitive equilibrium binding experiments, AMG 102 bound to human and cynomolgus monkey HGF with affinities of approximately 19 pmol/L and 41 pmol/L, respectively. However, AMG 102 did not detect mouse or rabbit HGF on immunoblots. Immunoprecipitation experiments showed that AMG 102 preferentially bound to the mature, active form of HGF, and incubation of AMG 102/HGF complexes with kallikrein protease indicated that AMG 102 had no apparent effect on proteolytic processing of the inactive HGF precursor. AMG 102 inhibited human and cynomolgus monkey HGF-induced c-Met autophosphorylation in PC3 cells with IC(50) values of 0.12 nmol/L and 0.24 nmol/L, respectively. AMG 102 also inhibited cynomolgus monkey HGF-induced migration of human MDA-MB-435 cells but not rat HGF-induced migration of mouse 4T1 cells. Epitope-mapping studies of recombinant HGF molecules comprising human/mouse chimeras and human-to-mouse amino acid substitutions showed that amino acid residues near the NH(2)-terminus of the beta-chain are critical for AMG 102 binding. Bound AMG 102 protected one trypsin protease cleavage site near the NH(2)-terminus of the beta-chain of human HGF, further substantiating the importance of this region for AMG 102 binding. Currently, AMG 102 is in phase II clinical trials in a variety of solid tumor indications. Mol Cancer Ther; 9(2); 400-9.
authors.affiliation: Amgen Inc., Thousand Oaks, California 91320-1799, USA. tburgess@amgen.com
authors.forename: Teresa L
authors.initials: TL
authors.lastname: Burgess
authors.forename: Jan
authors.initials: J
authors.lastname: Sun
authors.forename: Susanne
authors.initials: S
authors.lastname: Meyer
authors.forename: Trace S
authors.initials: TS
authors.lastname: Tsuruda
authors.forename: Jilin
authors.initials: J
authors.lastname: Sun
authors.forename: Gary
authors.initials: G
authors.lastname: Elliott
authors.forename: Qing
authors.initials: Q
authors.lastname: Chen
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Haniu
authors.forename: Will F
authors.initials: WF
authors.lastname: Barron
authors.forename: Todd
authors.initials: T
authors.lastname: Juan
authors.forename: Ke
authors.initials: K
authors.lastname: Zhang
authors.forename: Angela
authors.initials: A
authors.lastname: Coxon
authors.forename: Richard L
authors.initials: RL
authors.lastname: Kendall
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D018604:Epitope Mapping; D017228:Hepatocyte Growth Factor / Q000737:chemistry*; D006801:Humans; D015151:Immunoblotting; D020128:Inhibitory Concentration 50; D008252:Macaca fascicularis; D051379:Mice; D019151:Peptide Library; D010766:Phosphorylation; D011323:Primates; D011817:Rabbits; D011994:Recombinant Proteins / Q000737:chemistry
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019151:Peptide Library; D011994:Recombinant Proteins; C524459:rilotumumab; D017228:Hepatocyte Growth Factor